share_log

XOMA Corporation Announces Closing of Tender Offer

XOMA Corporation Announces Closing of Tender Offer

XOMA 公司宣布收购结束
GlobeNewswire ·  04/03 21:00

Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right

Kinnate股东将获得每股2.5879美元的现金加上或有价值权利

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KNTE) common stock for a price per share of $2.5879 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds resulting from Kinnate's sale of exarafenib and other pan-RAF program assets to Pierre Fabre Laboratories, as announced on March 1, 2024.

加利福尼亚州埃默里维尔,2024年4月3日(GLOBE NEWSWIRE)——在帮助生物技术公司实现改善人类健康目标方面发挥独特作用的生物技术特许权使用费汇总商XOMA公司(纳斯达克股票代码:XOMA)(“XOMA” 或 “公司”)今天宣布,该公司已成功完成先前宣布的收购Kinnate Biopharma Inc.(纳斯达克股票代码:KNTE)所有已发行股份的要约普通股每股价格为2.5879美元的现金(“现金金额”),外加一项不可交易的或有价值权利(“CVR”),以及现金金额,“要约价格”),代表在合并完成后一年内获得任何许可或出售Kinnate计划的净收益的85%的权利,以及Kinnate于2024年3月1日宣布的向皮尔法伯实验室出售艾沙拉非尼和其他泛英国皇家空军计划资产所得净收益的100%。

The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Tuesday, April 2, 2024 (the "Expiration Date"). As of the Expiration Date, a total of 38,258,681 shares of Kinnate common stock were validly tendered, and not validly withdrawn, representing approximately 81% of the outstanding shares of Kinnate common stock as of the Expiration Date. As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived. Immediately after the Expiration Date, XOMA irrevocably accepted for payment all shares validly tendered and not validly withdrawn and expects to promptly pay for such shares.

要约和相关的提款权在东部时间2024年4月2日星期二晚上 11:59(“到期日”)一分钟后到期。截至到期日,共有38,258,681股Kinnate普通股进行了有效投标,但未有效撤回,约占截至到期日Kinnate普通股已发行股份的81%。截至到期日,根据要约条款有效投标但未有效撤回的股票数量满足了最低投标条件,要约的所有其他条件均得到满足或免除。到期日过后,XOMA立即不可撤销地接受了所有已有效投标但未有效撤回的股份的付款,并期望立即支付此类股票。

Following the closing of the tender offer, XOMA merged Kinnate with and into a subsidiary, XRA 1 Corp. (the "Merger"), and all shares of Kinnate common stock that had not been validly tendered were converted into the right to receive the Offer Price. As a result of the Merger, Kinnate became a wholly owned subsidiary of XOMA. Prior to the opening of trading on The Nasdaq Stock Market LLC ("Nasdaq") on April 3, 2024, all shares of Kinnate common stock will cease trading on Nasdaq, and Kinnate intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.

要约结束后,XOMA将Kinnate与子公司XRA 1 Corp.(“合并”)合并为子公司,所有未经有效投标的Kinnate普通股均转换为获得要约价格的权利。合并后,Kinnate成为XOMA的全资子公司。在纳斯达克股票市场有限责任公司(“纳斯达克”)于2024年4月3日开盘交易之前,Kinnate普通股的所有股票将在纳斯达克停止交易,Kinnate打算立即使此类股票从纳斯达克退市,并根据经修订的1934年《证券交易法》注销注册。

Advisors
XOMA was represented by Gibson, Dunn & Crutcher LLP. Leerink Partners acted as lead financial advisor and Wilson Sonsini Goodrich & Rosati acted as legal counsel to Kinnate. Lazard also acted as a financial advisor to Kinnate.

顾问
XOMA 由 Gibson、Dunn & Crutcher LLP 代理。Leerink Partners担任首席财务顾问,威尔逊·桑西尼·古德里奇和罗萨蒂担任Kinnate的法律顾问。拉扎德还曾担任Kinnate的财务顾问。

About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of milestone and royalty assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit .

关于 XOMA 公司
XOMA是一家生物技术特许权使用费汇总商,在帮助生物技术公司实现改善人类健康的目标方面发挥着独特的作用。XOMA收购了与已获得制药或生物技术公司许可的商业前候选疗法相关的潜在未来经济学。当XOMA收购未来经济时,卖方将获得非稀释性、无追索权的资金,可用于推进其内部候选药物或用于一般公司用途。该公司拥有广泛且不断增长的里程碑资产和特许权使用费资产组合(资产定义为获得与潜在候选疗法发展相关的潜在未来经济的权利)。有关公司及其投资组合的更多信息,请访问 。

EXPLANATORY NOTE: Any references to "portfolio" in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to "assets" in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

解释性说明:本新闻稿中任何提及 “投资组合” 的内容都严格指与正在开发的一揽子药品相关的里程碑和/或特许权使用费。本新闻稿中任何提及 “资产” 的内容都严格指与正在开发的个别药物产品相关的里程碑和/或特许权使用费。

About Kinnate Biopharma Inc.
Kinnate Biopharma Inc. is a clinical-stage precision oncology company founded with a mission to inspire hope in those battling cancer by expanding on the promise of targeted therapies. Kinnate concentrates its efforts on addressing known oncogenic drivers for which there are currently no approved targeted therapies and to overcome the limitations associated with existing cancer therapies, such as non-responsiveness or the development of acquired and intrinsic resistance.

关于 Kinnate Biopharma Inc.
Kinnate Biopharma Inc. 是一家临床阶段的精准肿瘤学公司,成立的使命是通过扩大靶向疗法的前景来激发抗癌者的希望。Kinnate专注于解决目前尚无批准的靶向疗法的已知致癌驱动因素,并克服与现有癌症疗法相关的局限性,例如无反应性或获得性和内在耐药性的发展。

Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements, including statements regarding the payment and timing of payment of the Offer Price to former Kinnate common stockholders and the ability and timing of delisting of Kinnate's common stock. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "approximately," "expect," "may," "will," "could" or "should," the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA's performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks including the risk that XOMA does not achieve anticipated net cash after winding down Kinnate's operations and concluding remaining clinical trial activities, the risk that XOMA is unable to develop or otherwise enter into dispositions related to the Kinnate programs, and risks that the timing of the payment or delisting may be delayed. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

前瞻性陈述/解释性说明
本新闻稿中包含的某些陈述是前瞻性陈述,包括有关向前Kinnate普通股股东支付要约价和支付时间以及Kinnate普通股退市的能力和时机的陈述。在某些情况下,您可以通过诸如 “预期”、“大约”、“预期”、“可能”、“将”、“可能” 或 “应该” 等术语来识别此类前瞻性陈述,这些术语的否定词或类似表述。这些前瞻性陈述不能保证XOMA的表现,您不应过分依赖此类陈述。这些陈述基于可能不准确的假设,由于某些风险,实际结果可能与预期存在重大差异,包括XOMA在Kinnate结束业务和结束剩余临床试验活动后无法实现预期净现金的风险,XOMA无法制定或以其他方式进行与Kinnate计划相关的处置的风险,以及付款或退市时间可能延迟的风险。XOMA最近提交的10-K表以及向美国证券交易委员会提交的其他文件中详细描述了XOMA满足这些预期的其他潜在风险,这些文件可在美国证券交易委员会的网站上查阅 www.sec.gov。本新闻稿中的任何前瞻性陈述仅代表XOMA截至本新闻稿发布之日的信念和假设,不应以此作为其后任何日期的观点的依据。除非适用法律要求,否则XOMA不承担任何更新任何前瞻性陈述的义务。

XOMA Investor Contact XOMA Media Contact
Juliane Snowden Kathy Vincent
XOMA Corporation KV Consulting & Management
+1 646-438-9754 +1 310-403-8951
juliane.snowden@xoma.com kathy@kathyvincent.com
XOMA 投资者联系方式 XOMA 媒体联系人
朱丽安·斯诺登 凯西·文森特
XOMA 公司 KV 咨询与管理
+1 646-438-9754 +1 310-403-8951
juliane.snowden@xoma.com kathy@kathyvincent.com

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发